- Home
- HSTM vs SLS Comparison
HSTM vs SLS Comparison
Compare HSTM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSTM | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.2M | 924.5M |
| IPO Year | 1999 | 2007 |
Fundamental Metrics
Financial Performance| Metric | HSTM | SLS |
|---|---|---|
| Price | $28.72 | $12.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $28.00 | $10.00 |
| AVG Volume (30 Days) | 163.5K | ★ 6.3M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $304,064,000.00 | N/A |
| Revenue This Year | $9.45 | N/A |
| Revenue Next Year | $5.12 | $110.98 |
| P/E Ratio | $140.60 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $19.50 | $1.39 |
| 52 Week High | $31.11 | $15.88 |
Technical Indicators
Market Signals| Indicator | HSTM | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 52.09 |
| Support Level | $27.63 | $3.91 |
| Resistance Level | $30.00 | $15.88 |
| Average True Range (ATR) | 1.10 | 1.07 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 38.35 | 57.18 |
Price Performance
Historical ComparisonAbout HSTM HealthStream Inc.
HealthStream Inc provides SaaS based applications for healthcare organizations all designed to improve business and clinical outcomes by supporting the people who deliver patient care. The company is focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. It also provides its solutions to nursing schools and nursing students.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.